ProMIS Neurosciences Год IPO
Что обозначает Год IPO в ProMIS Neurosciences?
Год IPO ProMIS Neurosciences, Inc. является 2007
Какое определение для Год IPO?
Первичное публичное размещение акций - это тип публичного предложения, при котором акции компании обычно продаются институциональным инвесторам, которые, в свою очередь, впервые продают эти акции широкой публике на фондовой бирже.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Год IPO компаний в Health Care сектор на OTC по сравнению с ProMIS Neurosciences
Что делает ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Компании с год ipo похож на ProMIS Neurosciences
- G3 Exploration имеет Год IPO из 2006
- Evolis SA имеет Год IPO из 2006
- Unity Infraprojects имеет Год IPO из 2006
- News Invest имеет Год IPO из 2006
- AuStar Gold имеет Год IPO из 2006
- Sky and Space Global имеет Год IPO из 2006
- ProMIS Neurosciences имеет Год IPO из 2007
- Manas Resources имеет Год IPO из 2008
- Mastech Digital Inc имеет Год IPO из 2008
- MYR Inc имеет Год IPO из 2008
- Dana Inc имеет Год IPO из 2008
- American Water Works Co имеет Год IPO из 2008
- Chromadex Corp имеет Год IPO из 2008